TIDMONC
RNS Number : 5345T
Oncimmune Holdings PLC
25 March 2021
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS
RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN
WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE
UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC
OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD
CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT
JURISDICTION. PLEASE SEE THE IMPORTANT NOTICES AT THE OF THIS
ANNOUNCEMENT.
THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT
CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMATION,
OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE
OR DISPOSE OF ANY SECURITIES IN ONCIMMUNE HOLDINGS PLC OR ANY OTHER
ENTITY IN ANY JURISDICTION. NEITHER THIS ANNOUNCEMENT NOR THE FACT
OF ITS DISTRIBUTION, SHALL FORM THE BASIS OF, OR BE RELIED ON IN
CONNECTION WITH ANY INVESTMENT DECISION IN RESPECT OF ONCIMMUNE
HOLDINGS PLC.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES
OF THE MARKET ABUSE REGULATION (596/2014/EU) ("MAR"). UPON THE
PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW
CONSIDERED TO BE IN THE PUBLIC DOMAIN.
25 March 2021
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Result of Oversubscribed Equity Placing
Successful Equity Placing of GBP9.0 million
Further to the announcement at 07.45 a.m. today, Oncimmune
Holdings plc (AIM: ONC.L), the leading global immunodiagnostics
group , is pleased to announce the successful completion of its
oversubscribed Placing. The Placing was enlarged to accommodate
additional investor interest from both new and existing
investors.
The Placing has raised gross proceeds of GBP 9.0 million (before
commission and expenses) through the placing of 5,000,000 Placing
Shares with existing and new investors at the Placing Price of 180
pence.
The Placing Price represents a premium of approximately 5.0 per
cent. to the Company's mid-market closing price of 171.5 pence per
share on 24 March 2021, the Last Trading Day.
As previously disclosed in the Announcement, in parallel with
the Placing and reflecting the excess demand generated for Placing
Shares, Genostics, a company which held approximately 9.76 per
cent. of the Company's issued share capital prior to the Placing,
has provided a firm order to N+1 Singer to sell 2,948,486 ordinary
shares. Purchase orders have been secured from Placees for these
Genostics Sale Shares which will be transacted as market orders
after Second Admission has occurred, by which time all Placing
conditions will have been satisfied. Completion of these sale
orders will result in the reduction of Genostics' holding to 4.73
per cent. of the issued share capital as enlarged by the Placing, a
level which will facilitate Gene Group's planned corporate
activity. The Company has agreed in principle a restriction with
Genostics on the further sale of its residual ordinary shares in
the Company for 12 months.
Dr Adam M Hill, CEO of Oncimmune said: " Whilst Oncimmune is
already funded to meet previous market expectations, it has become
clear that an exciting opportunity exists to deploy additional
capital to accelerate the growth of the ImmunoINSIGHTS business in
the near term. We are therefore delighted with the outcome of this
oversubscribed equity financing round and the strong level of
support received from both existing and new investors, whom we
welcome to the Oncimmune share register.
"The Company is increasingly being recognised as a global leader
in the stratification of patients to optimise immune modulating
therapy, helping our partners to develop new classes of medicines
to treat patients with cancer, autoimmune disease and, more
latterly, infectious diseases. This funding will accelerate an
exciting growth trajectory for the Company as we scale up our
capacity to deliver a growing number of ImmunoINSIGHTS services
projects. At the same time, we are seeing good progress within our
EarlyCDT diagnostic product business.
"With the increasingly global nature of our client base and the
forecast rapid growth in our business over the next few years, the
Company looks forward to deploying this additional capital with
confidence in the growth prospects for the business."
Admission
Applications have been made to the London Stock Exchange for the
2,806,330 EI S/VCT Placing Shares and the 2,193,670 General Placing
Shares to be admitted to trading on AIM. The Placing Shares, when
issued, will be fully paid and will rank pari passu in all respects
with each other and with the existing ordinary shares of the
Company, including, without limitation, the right to receive all
dividends and other distributions declared, made or paid after the
date of issue.
It is expected that settlement of EIS/VCT Placing Shares and
First Admission will become effective at 8.00 a.m. on 29 March 2021
and that dealings in the 2,806,330 EIS/VCT Placing Shares will
commence at that time. It is expected that settlement of the
General Placing Shares and Second Admission will become effective
at 8.00 a.m. on 30 March 2021 and that dealings in the 2,193,670
General Placing Shares will commence at that time.
Total Voting Rights
On 30 March 2021, following Admission of both the EIS/VCT
Placing Shares and General Placing Shares, the Company's enlarged
issued share capital will comprise of 69,097,540 Ordinary Shares
with voting rights in the Company. This figure may be used by
shareholders in the Company as the denominator for the calculations
by which they will determine if they are required to notify their
interest in, or a change in the interest in, the share capital of
the Company under the FCA's Disclosure Guidance and Transparency
Rules.
Expected timetable of principal events
Allotment and issue of the EIS/VCT Placing 29 March 2021
Shares
First Admission and commencement of dealings 8.00 a.m. on
in the EIS/ VCT Placing Shares 29 March 2021
Allotment and issue of the General Placing 30 March 2021
Shares
Admission and commencement of dealings 8.00 a.m. on
in the General Placing Shares 30 March 2021
Except where stated, capitalised terms used in the announcement
have the same meaning as given in the Launch of Equity Placing via
ABB announcement issued earlier today.
For further information:
Oncimmune Holdings plc
Adam Hill, Chief Executive Officer
Matthew Hall, Chief Financial Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser)
Andrew Jones, Daniel Harris, Victoria Ayton
+44 (0)20 3829 5000
N+1 Singer (Joint Broker and Joint Bookrunner)
Aubrey Powell, Harry Gooden, Iqra Amin, James Fischer
+44 (0)20 7496 3000
WG Partners (Joint Broker and Joint Bookrunner)
David Wilson, Chris Lee
+44 (0)20 3705 9321
Media enquiries:
FTI Consulting
Ben Atwell, Michael Trace, Alex Davis
Oncimmune@fticonsulting.com
+44 (0)20 3727 1000
About Oncimmune
Oncimmune is a leading immunodiagnostics developer, primarily
focused on the growing fields of immuno-oncology, autoimmune
disease and infectious diseases. Oncimmune has a diversified and
growing revenue from its portfolio of diagnostic products to detect
early-stage cancer and a contract discovery and development
service-based platform, delivering actionable insights into
therapies to its pharmaceutical and biotech partners .
Our intimate understanding of the human immune system enables us
to harness its sophisticated response to disease to detect cancer
earlier and to support the development of better therapies. The key
to improving cancer survival is early detection and better
selection for therapy. As a company, we are driven by our passion
to improve cancer survival and to give people extra time.
Oncimmune's ImmunoINSIGHTS platform enables life science
organisations to optimise drug development and delivery, leading to
more effective targeted as well as safer treatments for patients.
Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and
help identify cancer on average four years earlier than standard
clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung,
targets a vast market estimated to grow to GBP3.8bn by 2024. With
over 200,000 tests already performed for patients worldwide and its
use being supported by peer reviewed data in over 12,000 patients,
we are poised to become an integral component of future lung cancer
detection programmes, globally.
Oncimmune, headquartered at its laboratory facility in
Nottingham, UK, and has a discovery research centre in Dortmund,
Germany.
For more information, visit www.oncimmune.com
This Announcement should be read in its entirety. In particular,
you should read and understand the information provided in the
"Important Notices" section below.
IMPORTANT NOTICES
Neither this announcement ("Announcement"), nor any copy of it,
may be taken or transmitted, published or distributed, directly or
indirectly, in whole or in part, in or into the United States,
Australia, Canada, Japan, New Zealand or the Republic of South
Africa or to any persons in any of those jurisdictions or any other
jurisdiction where to do so would constitute a violation of the
relevant securities laws of such jurisdiction (each, a "Restricted
Jurisdiction"). This Announcement is for information purposes only
and neither it, nor the information contained in it, shall
constitute an offer to sell or issue, or the solicitation of an
offer to buy, acquire or subscribe for any shares in the capital of
the Company in the United States, Australia, Canada, Japan, New
Zealand or the Republic of South Africa or any other state or
jurisdiction in which such offer or solicitation is not authorised
or to any person to whom it is unlawful to make such offer or
solicitation. Any failure to comply with these restrictions may
constitute a violation of securities laws of such
jurisdictions.
The Placing Shares have not been and will not be registered
under the U.S. Securities Act of 1933, as amended (the "Securities
Act"), or with any securities regulatory authority or under any
securities laws of any state or other jurisdiction of the United
States and may not be offered, sold, resold, pledged, transferred
or delivered, directly or indirectly, in or into the United States
except pursuant to an applicable exemption from, or in a
transaction not subject to, the registration requirements of the
Securities Act and in compliance with the securities laws of any
state or other jurisdiction of the United States.
No action has been taken by the Company, N+1 Singer or WG
Partners (together, the "Joint Bookrunners"), or any of their
respective directors, officers, partners, agents, employees,
affiliates, advisors, consultants or, in the case of the Joint
Bookrunners, persons connected with them as defined in the
Financial Services and Markets Act 2000, as amended ("FSMA")
(together, "Affiliates") that would permit an offer of the Placing
Shares or possession or distribution of this Announcement or any
other publicity material relating to such Placing Shares in any
jurisdiction where action for that purpose is required. Persons
receiving this Announcement are required to inform themselves about
and to observe any restrictions contained in this Announcement.
Persons (including, without limitation, nominees and trustees)
who have a contractual or other legal obligation to forward a copy
of this Announcement should seek appropriate advice before taking
any action.
This Announcement has not been approved by the Financial Conduct
Authority or the London Stock Exchange.
No offering document or prospectus will be made available in
connection with the matters contained or referred to in this
Announcement and no such offering document or prospectus is
required to be published, in accordance with Regulation (EU)
2017/1129 (the "EU Prospectus Regulation") or Regulation (EU)
2017/1129, as amended and retained in UK law on 31 December 2020 by
the European Union (Withdrawal) Act 2018 (the "EUWA") (the "UK
Prospectus Regulation"). No public offering of the Placing Shares
is being made by any person anywhere and the Company has not
authorised or consented to any such offering in relation to the
Placing Shares.
This Announcement is for information purposes only and is
directed only at: (a) in a Member State of the European Economic
Area ("EEA"), persons who are "qualified investors" within the
meaning of Article 2(e) of the EU Prospectus Regulation (as amended
and/or supplemented from time to time and includes any relevant
implementing measure in any Member State); and (b) in the United
Kingdom, persons who are "qualified investors" within the meaning
of Article 2(e) of the UK Prospectus Regulation who are also: (i)
"investment professionals" within the meaning of Article 19(5) of
the Financial Services and Markets Act 2000 (Financial Promotion)
Order 2005 (the "Order"); or (ii) persons falling within Article
49(2)(a) to (d) ("high net worth companies, unincorporated
associations, etc") of the Order; or (c) otherwise, persons to whom
it may otherwise be lawful to communicate them (all such persons in
(a), (b) and (c), together being referred to as "Relevant
Persons"). This Announcement must not be acted on or relied on by
persons who are not Relevant Persons.
This Announcement is not being distributed by, nor has it been
approved for the purposes of section 21 of FSMA by, a person
authorised under FSMA. This Announcement is being distributed and
communicated to persons in the United Kingdom only in circumstances
in which section 21(1) of FSMA does not require approval of the
communication by an authorised person.
This Announcement has been issued by, and is the sole
responsibility of, the Company. No responsibility or liability is
or will be accepted by, and no undertaking, representation or
warranty or other assurance, express or implied, is or will be made
or given by either of the Joint Bookrunners, or by any of their
respective Affiliates as to, or in relation to, the accuracy,
fairness or completeness of the information or opinions contained
in this Announcement or any other written or oral information made
available to or publicly available to any interested person or its
advisers, and any liability therefore is expressly disclaimed.
None of the information in this Announcement has been
independently verified or approved by either of the Joint
Bookrunners or any of their Affiliates. Save for any
responsibilities or liabilities, if any, imposed on the Joint
Bookrunners by FSMA or by the regulatory regime established under
it, no responsibility or liability whatsoever whether arising in
tort, contract or otherwise, is accepted by either of the Joint
Bookrunners or any of their respective Affiliates whatsoever for
the contents of the information contained in this Announcement
(including, but not limited to, any errors, omissions or
inaccuracies in the information or any opinions) or for any other
statement made or purported to be made by or on behalf of either of
the Joint Bookrunners or any of their respective Affiliates in
connection with the Company, the Placing Shares or the Placing or
for any loss, cost or damage suffered or incurred howsoever
arising, directly or indirectly, from any use of this Announcement
or its contents or otherwise in connection with this Announcement
or from any acts or omissions of the Company in relation to the
Placing. Each of the Joint Bookrunners and their respective
Affiliates accordingly disclaim all and any responsibility and
liability whatsoever, whether arising in tort, contract or
otherwise (save as referred to above) in respect of any statements
or other information contained in this Announcement and no
representation or warranty, express or implied, is made by either
of the Joint Bookrunners or any of their respective Affiliates as
to the accuracy, completeness or sufficiency of the information
contained in this Announcement.
N+1 Singer, which is authorised and regulated in the United
Kingdom by the Financial Conduct Authority (the "FCA") and is a
member of the London Stock Exchange, is acting as joint broker and
joint bookrunner to the Company. N+1 Singer is not acting for any
other person in connection with the matters referred to in this
Announcement and will not be responsible to anyone other than the
Company for providing the protections afforded to clients of N+1
Singer or for giving advice in relation to the matters referred to
in this Announcement. N+1 Singer has not authorised the contents of
this Announcement and, without limiting the statutory rights of any
person to whom this Announcement is issued, no representation or
warranty, express or implied, is made by N+1 Singer as to any of
the contents or the completeness of this Announcement and N+1
Singer does not accept responsibility for this Announcement and
accordingly disclaims all and any liability, whether arising in
tort, contract or otherwise, which it might otherwise be found to
have in respect of this Announcement.
WG Partners, which is authorised and regulated in the United
Kingdom by the FCA and is a member of the London Stock Exchange, is
acting as joint broker and joint bookrunner to the Company. WG
Partners is not acting for any other person in connection with the
matters referred to in this Announcement and will not be
responsible to anyone other than the Company for providing the
protections afforded to clients of WG Partners or for giving advice
in relation to the matters referred to in this Announcement. WG
Partners has not authorised the contents of this Announcement and,
without limiting the statutory rights of any person to whom this
Announcement is issued, no representation or warranty, express or
implied, is made by WG Partners as to any of the contents or the
completeness of this Announcement and WG Partners does not accept
responsibility for this Announcement and accordingly disclaims all
and any liability, whether arising in tort, contract or otherwise,
which it might otherwise be found to have in respect of this
Announcement.
Zeus Capital Limited ("Zeus Capital"), which is authorised and
regulated in the United Kingdom by the FCA and is a member of the
London Stock Exchange, is acting solely as the Company's nominated
adviser to the Company. Zeus Capital is not acting for any other
person in connection with the matters referred to in this
Announcement and will not be responsible to anyone other than the
Company for providing the protections afforded to clients of Zeus
Capital or for giving advice in relation to the matters referred to
in this Announcement. Zeus Capital has not authorised the contents
of this Announcement and, without limiting the statutory rights of
any person to whom this Announcement is issued, no representation
or warranty, express or implied, is made by Zeus Capital as to any
of the contents or the completeness of this Announcement and Zeus
Capital does not accept responsibility for this Announcement and
accordingly disclaims all and any liability, whether arising in
tort, contract or otherwise, which it might otherwise be found to
have in respect of this Announcement.
Certain statements in this Announcement are forward-looking
statements, which include all statements other than statements of
historical fact and which are based on the Company's expectations,
intentions and projections regarding its future performance,
anticipated events or trends and other matters that are not
historical facts. These forward-looking statements, which may use
words such as "aim", "anticipate", "believe", "could", "may",
"intend", "estimate", "expect" and words of similar meaning,
include all matters that are not historical facts. These
forward-looking statements involve risks, assumptions and
uncertainties that could cause the actual results of operations,
financial condition, liquidity and dividend policy and the
development of the industries in which the Company's businesses
operate to differ materially from the impression created by the
forward-looking statements. These statements are not guarantees of
future performance and are subject to known and unknown risks,
uncertainties and other factors that could cause actual results to
differ materially from those expressed or implied by such
forward-looking statements. Given those risks and uncertainties,
prospective investors are cautioned not to place undue reliance on
forward-looking statements. Forward-looking statements speak only
as of the date of such statements and, except as required by the
FCA, the London Stock Exchange or applicable law, the Company, the
Joint Bookrunners and their respective Affiliates undertakes no
obligation to update or revise publicly any forward-looking
statements, whether as a result of new information, future events
or otherwise.
No statement in this Announcement is intended to be a profit
forecast and no statement in this Announcement should be
interpreted to mean that earnings per share of the Company for the
current or future financial years would necessarily match or exceed
the historical published earnings per share of the Company.
This Announcement does not identify or suggest, or purport to
identify or suggest, the risks (direct or indirect) that may be
associated with an investment in the Placing Shares. Any investment
decision to buy Placing Shares in the Placing must be made solely
on the basis of publicly available information, which has not been
independently verified by the Joint Bookrunners. This Announcement
is not intended to provide the basis for any decision in respect of
the Company or other evaluation of any securities of the Company or
any other entity and should not be considered as a recommendation
that any investor should subscribe for, purchase, otherwise
acquire, sell or otherwise dispose of any such securities.
Recipients of this Announcement should conduct their own
investigation, evaluation and analysis of the business, data and
property described in this Announcement. Any indication in this
Announcement of the price at which the Company's shares have been
bought or sold in the past cannot be relied upon as a guide to
future performance. The price and value of securities can go down
as well as up.
The contents of this Announcement are not to be construed as
legal, business, financial or tax advice. Each shareholder or
prospective investor should consult with his or her or its own
legal adviser, business adviser, financial adviser or tax adviser
for legal, financial, business or tax advice.
In connection with the Placing, the Joint Bookrunners and any of
their respective Affiliates, acting as investors for their own
account, may take up a portion of the Placing Shares in the Placing
as a principal position and in that capacity may retain, purchase,
sell, offer to sell for the own accounts or otherwise deal for
their own account in such Placing Shares and other securities of
the Company or related investments in connection with the Placing
or otherwise. Accordingly, references to Placing Shares being
offered, acquired, placed or otherwise dealt in should be read as
including any issue or offer to, or acquisition, placing or dealing
by, the Joint Bookrunners and any of their respective Affiliates
acting in such capacity. In addition, the Joint Bookrunners and any
of their respective Affiliates may enter into financing
arrangements (including swaps, warrants or contracts for
difference) with investors in connection with which the Joint
Bookrunners and any of their respective Affiliates may from me to
me acquire, hold or dispose of shares. The Joint Bookrunners do not
intend to disclose the extent of any such investment or
transactions otherwise than in accordance with any legal or
regulatory obligations to do so.
The Placing Shares to be issued pursuant to the Placing will not
be admitted to trading on any stock exchange other than the London
Stock Exchange.
Neither the content of the Company's website (or any other
website) nor the content of any website accessible from hyperlinks
on the Company's website (or any other website) is incorporated
into, or forms part of, this Announcement.
UK Product Governance Requirements
Solely for the purposes of the product governance requirements
contained within the FCA Handbook Product Intervention and Product
Governance Sourcebook (the "UK Product Governance Rules"), and
disclaiming all and any liability, whether arising in tort,
contract or otherwise, which any 'manufacturer' (for the purposes
of the UK Product Governance Rules) may otherwise have with respect
thereto, the Placing Shares have been subject to a product approval
process, which has determined that the Placing Shares are: (i)
compatible with an end target market of (a) retail clients, as
defined in point (8) of Article 2 of Regulation (EU) No 2017/565 as
it forms part of domestic law by virtue of the EUWA, (b) investors
who meet the criteria of professional clients as defined in
Regulation (EU) No 600/2014 as it forms part of domestic law by
virtue of the EUWA and (c) eligible counterparties as defined in
chapter 3 of the FCA Handbook Conduct of Business Sourcebook
("COBS"); and (ii) eligible for distribution through all
distribution channels as are permitted by Directive 2014/65/EU (the
"UK Target Market Assessment"). Notwithstanding the UK Target
Market Assessment, distributors should note that: the price of the
Placing Shares may decline and investors could lose all or part of
their investment; the Placing Shares offer no guaranteed income and
no capital protection; and an investment in the Placing Shares is
compatible only with investors who do not need a guaranteed income
or capital protection, who (either alone or in conjunction with an
appropriate financial or other adviser) are capable of evaluating
the merits and risks of such an investment and who have sufficient
resources to be able to bear any losses that may result therefrom.
The UK Target Market Assessment is without prejudice to the
requirements of any contractual, legal or regulatory selling
restrictions in relation to the Placing. Furthermore, it is noted
that, notwithstanding the UK Target Market Assessment, the Joint
Bookrunners will only procure investors who meet the criteria of
professional clients and eligible counterparties. For the avoidance
of doubt, the UK Target Market Assessment does not constitute: (a)
an assessment of suitability or appropriateness for the purposes of
COBS; or (b) a recommendation to any investor or group of investors
to invest in, or purchase, or take any other action whatsoever with
respect to the Placing Shares. Each distributor is responsible for
undertaking its own target market assessment in respect of the
Placing Shares and determining appropriate distribution
channels.
EU Product Governance Requirements
Solely for the purposes of the product governance requirements
contained within: (a) EU Directive 2014/65/EU on markets in
financial instruments, as amended ("MiFID II"); (b) Articles 9 and
10 of Commission Delegated Directive (EU) 2017/593 supplementing
MiFID II; and (c) local implementing measures (together, the "MiFID
II Product Governance Requirements"), and disclaiming all and any
liability, whether arising in tort, contract or otherwise, which
any 'manufacturer' (for the purposes of the MiFID II Product
Governance Requirements) may otherwise have with respect thereto,
the Shares have been subject to a product approval process, which
has determined that the Shares are: (i) compatible with an end
target market of retail clients and investors who meet the criteria
of professional clients and eligible counterparties, each as
defined in MiFID II; and (ii) eligible for distribution through all
distribution channels as are permitted by MiFID II (the "EU Target
Market Assessment"). Notwithstanding the EU Target Market
Assessment, distributors should note that: the price of the Shares
may decline and investors could lose all or part of their
investment; the Shares offer no guaranteed income and no capital
protection; and an investment in the Placing Shares is compatible
only with investors who do not need a guaranteed income or capital
protection, who (either alone or in conjunction with an appropriate
financial or other adviser) are capable of evaluating the merits
and risks of such an investment and who have sufficient resources
to be able to bear any losses that may result therefrom. The EU
Target Market Assessment is without prejudice to the requirements
of any contractual, legal or regulatory selling restrictions in
relation to the placing. Furthermore, it is noted that,
notwithstanding the EU Target Market Assessment, the Joint
Bookrunners will only procure investors who meet the criteria of
professional clients and eligible counterparties.
For the avoidance of doubt, the EU Target Market Assessment does
not constitute: (a) an assessment of suitability or appropriateness
for the purposes of MiFID II; or (b) a recommendation to any
investor or group of investors to invest in, or purchase or take
any other action whatsoever with respect to the Placing Shares.
Each distributor is responsible for undertaking its own target
market assessment in respect of the Placing Shares and determining
appropriate distribution channels.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ROIEADDSASXFEFA
(END) Dow Jones Newswires
March 25, 2021 10:01 ET (14:01 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024